Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSCLF)

Satellos Bioscience Inc (MSCLF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 89,860
  • Shares Outstanding, K 185,507
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,510 K
  • EBIT $ -21 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.10
  • Most Recent Earnings $-0.03 on 11/14/25
  • Next Earnings Date 11/12/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +2,497,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4419 +9.62%
on 11/14/25
0.5878 -17.59%
on 11/17/25
-0.0056 (-1.14%)
since 11/05/25
3-Month
0.4419 +9.62%
on 11/14/25
0.6346 -23.67%
on 10/10/25
+0.0099 (+2.09%)
since 09/05/25
52-Week
0.3774 +28.35%
on 06/16/25
0.9350 -48.19%
on 12/11/24
-0.1156 (-19.27%)
since 12/05/24

Most Recent Stories

More News
Satellos to Participate in December Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy

Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors

Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors Completed IND submission...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos to Participate in November Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos to Participate in November Investor Conferences

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy

First returning adult patient from Phase 1b study recently dosed; additional returning patients being scheduled 11-month open-label...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos Bioscience Reports Positive Phase 1 Trial Results for Duchenne Muscular Dystrophy Treatment

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Satellos...

MSCLF : 0.4844 (+3.06%)
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy

Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247 ...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy

Regulatory submissions filed in the U.S., UK, Europe, Serbia and Australia ...

MSCLF : 0.4844 (+3.06%)
MSCL.TO : 0.67 (unch)

Business Summary

Satellos Bioscience Inc. is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company's lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience...

See More

Key Turning Points

3rd Resistance Point 0.5269
2nd Resistance Point 0.5147
1st Resistance Point 0.4995
Last Price 0.4844
1st Support Level 0.4721
2nd Support Level 0.4599
3rd Support Level 0.4447

See More

52-Week High 0.9350
Fibonacci 61.8% 0.7220
Fibonacci 50% 0.6562
Fibonacci 38.2% 0.5904
Last Price 0.4844
52-Week Low 0.3774

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar